Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
130
resultados
Última actualización
02/08/2026 [07:28:00]
Resultados 25 a 50 de 130
Resumen de: WO2026115801A1
Provided is an inflammatory bowel disease testing method. This inflammatory bowel disease testing method comprises (1) a step for detecting biomarkers in a biological sample collected from a subject. The biomarkers include: proHp and LRG; or proHp and CRP.
Resumen de: US20260152808A1
The present invention relates to a score (TOPOSCORE) for describing eubiosis or dysbiosis in an individual, that can be used, inter alia, for determining if a patient is likely to respond to an immune-oncology treatment, more precisely, a treatment comprising administration of an immune checkpoint inhibitor (ICI). The TOPOSCORE represents a robust biomarker predicting immunosensitivity and immunoresistance to ICI on an individual basis.
Resumen de: US20260153518A1
0000 A method for detecting an immune-mediated inflammatory disease characterized by an increase in expression of MMP12, in a subject, a diagnostic drug containing a substance that specifically interacts with MMP12, and a therapeutic agent containing an MMP12 inhibitory substance.
Resumen de: CN118581207A
The invention provides a marker for diagnosing systemic inflammation and application, the marker comprises ADGRE3mRNA or ADGRE3 protein, or ADGRE3mRNA fragment and ADGRE3 protein fragment, the marker content in samples of systemic inflammation patients and healthy people has significant difference, clinical verification shows that the marker is high in diagnosis sensitivity and specificity, and the marker can be applied to diagnosis of systemic inflammation. Therefore, systemic inflammation can be accurately diagnosed by detecting the transcription level of ADGRE3 mRNA or the expression level of ADGRE3 protein in an individual sample. Compared with an existing inflammation marker, the ADGRE3 mRNA and the ADGRE3 protein have higher sensitivity and specificity in the aspect of diagnosis of systemic inflammation.
Resumen de: US20260146996A1
Provided is an examination method for irAE enteritis, said examination method comprising a detection step for detecting, as an indicator of ulcerous colitis-like irAE enteritis, an antibody that immunologically reacts with a fragment of, or the entirety of, integrin ανβ6 in a specimen.
Resumen de: CN122075500A
The invention discloses application of a hyocholic acid bile acid component in preparation of a medicine for treating irritable bowel syndrome. The research finds that the content of hyocholic acid components in peripheral excrement of an IBS-D patient treated by the traditional Chinese medicine is obviously increased. Moreover, the hyocholic bile acid component is significantly reduced in the peripheral fecal sample of the IBS-D patient as compared to the health control group. The further research finds that hyodeoxycholic acid and natural traditional Chinese medicine pulvis fellis suis can reduce the peripheral serotonin level by inhibiting the activity of tryptophan hydroxylase 1, and the symptoms of diarrhea and stomachache of mice induced by TNBS are remarkably improved. The application value of the hyocholic acid bile acid component in treatment of IBS-D. The invention provides the application value of the hyocholic acid bile acid component.
Resumen de: WO2016167365A1
Provided is a marker for determining a mental disease, which can be used for an objective diagnosis of a mental disease. A marker for determining a metal disease, which comprises at least one enterobacterium selected from those belonging to Bifidobacterium, Lactobacillus, Lactobacillus brevis, Lactobacillus reuteri subgroup, Lactobacillus sakei subgroup, Atopobium cluster, Bacteroides fragilis group, Enterococcus, Clostridium coccoides group, Clostridium leptum subgroup, Staphylococcus, Clostridium perfringens and Enterobacteriaceae.
Resumen de: US20260140112A1
Provided herein is a peptide array comprising a plurality of flagellin peptides corresponding to highly conserved peptide regions. For example, the peptide array comprises a plurality of Lachnospiraceae flagellin peptides, which can be selected from a hinge region of Lachnospiraceae flagellin. Also provided is antibody of fragment thereof that binds to one or more of the plurality of the flagellin peptides in the peptide array. The peptide array and antibody are useful in determining an immunosignature from a biological sample from a subject. The immunosignature is useful in diagnosis of an immune-mediated disease, in monitoring progression of an immune-mediated disease, in identifying subjects susceptible to certain treatments, and in monitoring treatment response.
Resumen de: US20260142011A1
Provided herein are systems and methods for optimizing a biological therapy regimen for a subject. The subject may be a patient diagnosed with an immune mediated inflammatory disease. In some embodiments, the systems and methods may involve inputting patient data into a model to forecast a drug concentration level in a patient and establish a dosing regimen for maintaining a pre-specified threshold drug concentration level in the patient. The pre-specified threshold may be a target concentration level for effective treatment of the immune mediated inflammatory disease in the patient.
Resumen de: EP4744731A2
0001 The present invention relates to an antibody for treating or preventing autoimmune diseases. The antibody of the present invention comprises a heavy chain variable region set forth in SEQ ID NO: 1 and a light chain variable region set forth in SEQ ID NO: 6.
Resumen de: EP4745571A1
0001 A method for determining a mucosal disorder in a gastrointestinal tract includes: a preparation step for preparing a biological sample collected from a subject to which an endoscopic dye compound has been administered; a measurement step for measuring an amount of the endoscopic dye compound or a metabolite thereof in the biological sample; a comparison step for comparing the measured amount of the endoscopic dye compound or a metabolite thereof with a reference value; and a determination step for determining that the subject is highly likely to have a mucosal disorder in the gastrointestinal tract if the measured amount of the endoscopic dye compound or a metabolite thereof is equal to or greater than the reference value.
Resumen de: CN122060665A
The invention relates to the technical field of cell biology, in particular to a construction method of children Crohn's disease intestinal tract organoid. According to the invention, a natural immune microenvironment is established by using intestinal tissues from children patients suffering from Crohn's disease and immune cells residing in the tissues, so that the experimental limitation of insufficient peripheral blood volume of children is avoided; p-nitro branstatin is innovatively introduced into a culture system, so that the formation of organoid is effectively increased. Compared with the traditional inhibitor blebbistatin of NMII, the p-nitro branstatin has the advantages that the defects of poor solubility and poor light stability are avoided, the composition stability of the culture medium is favorably maintained, and the p-nitro branstatin is more suitable for a system which is a gas-liquid type organ and is longer in liquid change interval and needs to be cultured for a long time. The invention provides a new model for exploration of related mechanisms of children Crohn's disease and evaluation of drug efficacy.
Resumen de: CN122056348A
The invention discloses application of rice bran in preparation of food or health care products with functions of relaxing bowels and promoting intestinal peristalsis, and relates to the field of functional food. According to the application, the combination of active components of unsaturated fatty acid-phenolic acid-amino acid derivatives in the rice bran is defined through systematic component analysis, richer material basis explanation is provided for the bowel relaxing effect of the rice bran, the effective concentration range and the optimal concentration of the rice bran are quantified, and a direct experimental basis is provided for product dosage design.
Resumen de: CN122042980A
The invention discloses application of retin-1 in prediction of an intestinal lesion range of ulcerative colitis, and relates to the technical field of inflammatory bowel disease markers. The serum Omentin-1 level can accurately predict the intestinal lesion range of the UC patient in the active period. Therefore, the invention provides a new means for managing the dynamic change of the disease of the UC patient clinically, and has a better clinical application prospect.
Resumen de: CN122005567A
The invention belongs to the technical field of biomedicine, and particularly relates to application of ME1 in preparation of a medicine for preventing and/or treating inflammatory bowel diseases. The invention discloses an application of an ME1 inhibitor in preparation of drugs for preventing and/or treating inflammatory bowel diseases, and an application of a substance for detecting ME1 in preparation of drugs for diagnosing or detecting inflammatory bowel diseases. The action effect of ME1 * in disease treatment is evaluated through a mouse IBD model induced by dextran sodium sulfate DSS and trinitrobenzene sulfonic acid TNBS, so that a new strategy and method are provided for clinical intervention of IBD. In addition, the invention also clarifies the application of the ME1 as a high-specificity biomarker in IBD diagnosis, and further expands the comprehensive value of the ME1 in disease prevention and treatment.
Resumen de: CN122012320A
The invention discloses application of bacteroides xylanolyticum capable of promoting intestinal bacteria to produce propionic acid and a composition of the bacteroides xylanolyticum in relieving ulcerative colitis, and belongs to the technical field of microorganisms. The bacteroides xylanolyticus NSP016 disclosed by the invention can quickly utilize konjac glucomannan, and the composition of the bacteroides xylanolyticus and konjac glucomannan can improve the rise of histopathologic score of mice with ulcerative colitis, maintain the integrity of intestinal barriers, reduce the oxidative stress level and remarkably reduce the level of clinical diagnosis markers of colitis, so that the clinical diagnosis of colitis is facilitated. The effect is better than that of a clinical medicine mesalazine. The bacteroides xylanolyticum NSP016 and the composition thereof disclosed by the invention have very wide application prospects in the aspect of preparing foods, pharmaceutical compositions, health-care products or feed additives for relieving ulcerative colitis.
Resumen de: KR20240124203A
The present invention relates to a companion diagnostic biomarker composition for predicting an astragalin treatment response to inflammatory bowel disease. By confirming that the expression of stathmin or regulator of chromosome condensation 2 (RCC2) is specifically reduced in a response group having an astragalin treatment response to inflammatory bowel disease, the present invention can be used as the companion diagnostic biomarker composition for predicting an astragalin treatment response to inflammatory bowel disease.
Resumen de: CN121991171A
The invention belongs to the technical field of bioactive peptides, and provides a small red bean polypeptide for preventing and treating ulcerative colitis and application of the small red bean polypeptide, and the amino acid sequence of the small red bean polypeptide is IFNNDPNNHP. The small red bean polypeptide can significantly reduce the DAI score of a mouse with DSS colitis, relieve the shortening of the colon length of the mouse with DSS colitis and improve the erosion and ulcer degree of the colonic mucosa, and has good prevention and treatment effects on ulcerative colitis; meanwhile, the preparation method is simple and easy for industrial production; certain drug research and development and clinical application values are realized.
Resumen de: WO2026097001A2
The present disclosure is related to ex vivo methods and devices for identifying a presence of or predicting a risk for a condition in a subject, wherein the risk or condition is correlated with an oxidation-redox potential (ORP) of a biological sample obtained from the subject, such as a fecal sample. The methods and devices of the present disclosure can be used to diagnose and monitor gut microbiome health and assess the risk and/or presence of conditions such as obesity, metabolic dysfunction associated steatotic liver disease (MASLD), type 2 diabetes, hyperlipidemia, hypertension, cardiovascular disease, a gut specific condition, irritable bowel syndrome, an inflammatory bowel disease, ulcerative colitis, Crohn's disease, a Clostridium difficile infection, or any combination thereof based on an ORP of the subject's sample.
Resumen de: WO2025003436A1
The present application provides an ultrasensitive colorimetric assay as well as an early biomarker for patient monitoring and medical treatment of patients suffering from a possible mitochondrial dysfunction, inflammatory bowel disease, particularly Crohn's disease. The ultrasensitive colorimetric assay measures the level of L-citrulline in a plasma or serum sample; and when the level of L-citrulline in plasma or serum decreases or falls even below 30 µmol L-citrulline, this indicates a mitochondrial cell disorder caused by a relapse or an increase in intestinal inflammation due to a flare of Crohn's disease. A method of detecting and treating the mitochondrial dysfunction is also provided.
Resumen de: CN121971613A
The invention provides application of ANKRD13A as a target spot in preparation of an anti-enteritis drug, relates to the technical field of biomedicine, and is technically characterized in that application of ANKRD13A as a target spot in preparation of an anti-enteritis drug is provided. According to the application, the mRNA expression level of ANKRD13A in intestinal mucosa of adult and pediatric ulcerative colitis (UC) patients is proved to be obviously lower than that of a healthy control group by analyzing a GEO public data set; an Ankrd13a gene knockout mouse model is constructed, and it is found that gene deletion in a steady state does not affect colon development and functions; after acute colitis is induced by DSS, the death rate of knockout mice is increased, the colitis susceptibility is increased, the colon is shortened, intestinal epithelium injury is aggravated, and immune cell infiltration is increased. According to the application, the key regulation effect of the ANKRD13A in ulcerative colitis is defined, an experimental basis is provided for developing the ANKRD13A as an anti-enteritis drug target and a diagnostic marker, and the related drug can be used for preventing and treating enteritis.
Resumen de: CN121971661A
The invention provides a radiopharmaceutical and application thereof, and relates to the technical field of nuclear medicine, the radiopharmaceutical provided by the invention can be used as an integrin alpha4beta7 imaging agent, and imaging diagnosis can be carried out on focuses of diseases (such as inflammatory bowel diseases or tumor diseases) related to positive expression of integrin alpha4beta7 by utilizing a PET imaging technology of nuclear medicine. A chelating part in the integrin alpha4beta7 radiopharmaceutical can be replaced by NOTA chelating agents, NODAGA chelating agents, DOTAGA chelating agents, THP chelating agents and TRAP chelating agents, and the integrin alpha4beta7 radiopharmaceutical can be used for labeling < 68 > Ga metal nuclides, < 61 > Cu metal nuclides, < 64 > Cu metal nuclides and < 177 > Lu metal nuclides, so that PET imaging and nuclide treatment of various nuclides are further realized.
Resumen de: CN121950604A
The invention discloses an application of intestinal Rosebaria capable of promoting intestinal bacteria to produce valeric acid and a composition of the intestinal Rosebaria in relieving ulcerative colitis, and belongs to the technical field of microorganisms. According to the intestinal Rosiberia NSP017 disclosed by the invention, the konjac glucomannan can be quickly utilized, and the composition of the intestinal Rosiberia and the konjac glucomannan can be used for improving the disease activity index and spleen enlargement of a mouse with ulcerative colitis, maintaining the integrity of an intestinal barrier, reducing the oxidative stress level, and improving the ulcerative colitis activity index and the spleen enlargement of the mouse with ulcerative colitis, so that the intestinal Rosiberia NSP017 can be used for treating ulcerative colitis. The level of a clinical diagnosis marker for colitis is remarkably reduced, the effect is superior to that of a clinical medicine mesalazine, and it is found that the intestinal Rosebawnella NSP017 can promote intestinal bacteria of mice with colitis to recover the capacity of producing valeric acid. The intestinal Rosibula sp. NSP017 and the composition of the intestinal Rosibula sp. NSP017 have very wide application prospects in the aspect of preparing foods, pharmaceutical compositions, health-care products or feed additives for relieving ulcerative colitis.
Resumen de: CN121955382A
The invention discloses a protein marker for differential diagnosis of intestinal extracorporeal natural killer/T cell lymphoma and application of the protein marker. The protein marker is composed of COL6A3 and MFAP2 protein. Or the protein is composed of ADAMTS4, COL6A3 and MFAP2 protein. The invention also provides application of a reagent for detecting the protein in preparation of a kit for diagnosing intestinal natural killer cell/T cell lymphoma or evaluating the occurrence risk of the intestinal natural killer cell/T cell lymphoma. According to the invention, the technical bottleneck of difficulty in pathological diagnosis caused by superficial endoscopic biopsy sample of the intestinal ENKTL is effectively solved, and ENKTL can be accurately identified from ulcerative colitis, diffuse large B-cell lymphoma and colon cancer. The method is simple and convenient to operate, the selected antibody is strong in signal and clear in background in IHC detection, a quantitative result with good repeatability and high specificity can be obtained by combining an H-score scoring system, and objectivity and accuracy of pathological diagnosis are remarkably improved.
Nº publicación: AU2024362918A1 30/04/2026
Solicitante:
ODYSSEY THERAPEUTICS INC
ODYSSEY THERAPEUTICS, INC.
Resumen de: AU2024362918A1
This disclosure relates generally to methods for treating an inflammatory bowel disease ("IBD", e.g., Crohn's disease or ulcerative colitis) in a patient. More particularly, this disclosure relates to methods for selecting a therapy for treating a patient suffering from an IBD. In embodiments, the foregoing can also be used to assess the severity of the IBD. The predictive aspects of said methods can facilitate and expedite the identification and stratification of IBD patient populations that are responsive to treatment with a RIPK2 inhibitor. The foregoing methods can further include treating the IBD by administering a RIPK2 inhibitor to the patient.
BOPI
Sede Electrónica
